Aubagio (teriflunomide) may lead to reversible nail loss, researchers at Italy’s University of Bologna reported after reviewing the case of a 55-year-old woman with relapsing-remitting multiple sclerosis.
They described ... Read more
Sanofi Genzyme will discuss three of its multiple sclerosis therapies at the American Academy of Neurology annual meeting in Boston, April 22-28. The presentations will cover two approved treatments ... Read more
Sanofi, a global healthcare leader, and the Institut Pasteur, an internationally renowned center for biomedical research, recently honored four researchers with the Sanofi – Institut Pasteur Awards ... Read more
Sanofi subsidiary and rare disease treatment specialist Genzyme has just announced the successful enrollment of the first participant in their multicenter Phase II clinical trial for the company’s ... Read more
Pin It on Pinterest